FDA Lifts Hold on Intellia’s Phase 3 Gene-Editing Trial for Deadly Heart Disease

Intellia Therapeutics gets FDA approval to resume its Phase 3 trial for nexiguran ziclumeran, a gene-editing treatment for ATTR-CM heart disease, boosting shares by 6%.